For the quarter ended September 2025, Cencora (COR) reported revenue of $83.73 billion, up 5.9% over the same period last year. EPS came in at $3.84, compared to $3.34 in the year-ago quarter.
The reported revenue represents a surprise of +0.69% over the Zacks Consensus Estimate of $83.16 billion. With the consensus EPS estimate being $3.79, the EPS surprise was +1.32%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Cencora performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Total U.S. Healthcare Solutions: $75.79 billion versus the four-analyst average estimate of $75.11 billion. The reported number represents a year-over-year change of +5.7%.
- Revenue- Total International Healthcare Solutions: $7.94 billion versus $8 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.
- Revenue- Intersegment eliminations: $-4.94 million versus the three-analyst average estimate of $-4.37 million. The reported number represents a year-over-year change of +60.3%.
View all Key Company Metrics for Cencora here>>>
Shares of Cencora have returned +11.6% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
